CEFOTAXIME SODIUM FOR INJECTION, BP 250 MG — DIN 02261499
CEFOTAXIME (CEFOTAXIME SODIUM) : 250 MG · HOSPIRA HEALTHCARE ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is CEFOTAXIME SODIUM FOR INJECTION, BP?
CEFOTAXIME SODIUM FOR INJECTION, BP 250 MG contains CEFOTAXIME (CEFOTAXIME SODIUM) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02261499, held by HOSPIRA HEALTHCARE ULC, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled pre market, status dated 21-Mar-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CEFOTAXIME SODIUM FOR INJECTION, BP used for?
Cefotaxime Sodium for Injection BP may be indicated for the treatment of infections caused by susceptible strains of the designated micro-organisms in the diseases listed, including lower respiratory tract infections, urinary tract infections, bacteremia/septicemia, skin infections, intra-abdominal infections, gynecological infections, and central nervous system infections. It may also be used prophylactically to reduce the incidence of certain infections in patients undergoing elective surgical procedures or cesarian section.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefotaxime cost around the world?
Cefotaxime is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 15 | 19 | ZAR███.██ |
| Saudi Arabia | public | 18 | 18 | SAR███.██ |
| Morocco | PPV (public price) | 5 | 10 | MAD███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
61 pack listings across 51 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Cefotaxime pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Cefotaxime in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Cefotaxime, across 21 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| STERIMAX INC | 3 | 2 | CEFOTAXIME SODIUM FOR INJECTION, BP | Sourceable in Canada |
| HOECHST ROUSSEL CANADA INC. | 4 | 0 | CLAFORAN ADD-VANTAGE VIALS 1GM/VIAL, CLAFORAN PWS INJ 1.0GM/VIAL, CLAFORAN PWS INJ 2.0GM/VIAL, CLAFORAN PWS INJ 500MG/VIAL | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 4 | 0 | CEFOTAXIME SODIUM FOR INJECTION, BP | No marketed DIN |
| ROUSSEL CANADA INC. | 4 | 0 | CLAFORAN 0.5GM/VIAL, CLAFORAN 1GM/VIAL, CLAFORAN 2GM/VIAL, CLAFORAN INJ 1GM/ADD-VANTAGE VIAL | No marketed DIN |
| AUROBINDO PHARMA LIMITED (UNIT VI) | 3 | 0 | CEFOTAXIME SODIUM FOR INJECTION BP | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | CLAFORAN - PWS INJ 1.0G/VIAL, CLAFORAN - PWS INJ 2.0G/VIAL, CLAFORAN - PWS INJ 500MG/VIAL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | Box of 10 vials containing 250 mg, 500 mg, 1.0 and 2.0 g of cefotaxime (as cefotaxime sodium). |
| Storage | Store at controlled room temperature (15 to 30°C) protected from light. Reconstituted solutions maintain satisfactory potency for 12 hours at room temperature (25°C) and for 24 hours under refrigeration (2 to 8°C). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Cefotaxime |
|---|---|
| ATC code | J01DD01 |
| AHFS class | 08:12.06.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02261499 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2261499 |
| Brand name | CEFOTAXIME SODIUM FOR INJECTION, BP |
| Generic / active ingredient | CEFOTAXIME (CEFOTAXIME SODIUM) : 250 MG |
| Market authorization holder | HOSPIRA HEALTHCARE ULC |
| Health Canada schedule | Prescription |
| ATC code | J01DD01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DD |
| Current status | CANCELLED PRE MARKET |
| Status date | 21-Mar-2018 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 21 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02434091 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 2 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02434105 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | 02352176 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 0.5 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | 02352168 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | 02352184 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261502 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | 02434083 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 2.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261529 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261510 |
| CLAFORAN - PWS INJ 1.0G/VIAL | 1 G | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02225093 |
2 · Same class — other molecules in ATC J01DD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ceftriaxone | CEFTRIAXONE FOR INJECTION · CEFTRIAXONE FOR INJECTION USP · CEFTRIAXONE INJECTION, USP · CEFTRIAXONE SODIUM FOR INJECTION · +7 more | 41 | 13 | Yes |
| Ceftazidime | CEFTAZIDIME FOR INJECTION BP · CEFTAZIDIME FOR INJECTION, BP · CEFTAZIDIME FOR INJECTION, USP · CEPTAZ INJ 10GM/VIAL · +13 more | 23 | 6 | Yes |
| Cefixime | AURO-CEFIXIME · SUPRAX · SUPRAX - TAB 200MG | 8 | 4 | Yes |
| Cefotaxime | CEFOTAXIME SODIUM FOR INJECTION BP · CEFOTAXIME SODIUM FOR INJECTION, BP · CLAFORAN - PWS INJ 1.0G/VIAL · CLAFORAN - PWS INJ 2.0G/VIAL · +9 more | 21 | 2 | Yes |
| Ceftizoxime | CEFIZOX | 2 | 0 | Not in Canada |
| Cefpodoxime | ORELOX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEFOTAXIME SODIUM FOR INJECTION, BP called?
The same molecule, Cefotaxime, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CETAXON | Latin | Morocco |
| Kefotax | Latin | Morocco, South Africa |
| CEFOTAX | Latin | Bahrain |
| CLAFORAN | Latin | Morocco |
| Oritaxim | Latin | South Africa |
| KEFOTAX IM | Latin | Morocco |
| KEFOTAX IV | Latin | Morocco |
| Klafotaxim | Latin | South Africa |
| SEFOXIME | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.